Sprint Bioscience AB (publ) (STO:SPRINT)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.5420
-0.0100 (-1.81%)
Aug 1, 2025, 5:09 PM CET
-1.81%
Market Cap57.19M
Revenue (ttm)62.38M
Net Income (ttm)-20.85M
Shares Out105.52M
EPS (ttm)-0.30
PE Ration/a
Forward PE5.42
Dividendn/a
Ex-Dividend Daten/a
Volume180,604
Average Volume127,935
Open0.5600
Previous Close0.5520
Day's Range0.5420 - 0.5680
52-Week Range0.3600 - 2.2100
Beta-0.63
RSI52.85
Earnings DateAug 22, 2025

About CTI BioPharma

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 38
Stock Exchange Nasdaq Stockholm
Ticker Symbol SPRINT
Full Company Profile

Financial Performance

In 2024, Sprint Bioscience AB's revenue was 66.14 million, an increase of 27.97% compared to the previous year's 51.69 million. Losses were -18.28 million, 4072.8% more than in 2023.

Financial Statements

News

There is no news available yet.